Shots:

• The US FDA has granted approval of Ventana ALK (D5F3) as a CDx assay to identify ALK+ NSCLC patients eligible for treatment with Pfizer's drug Lorbrena (lorlatinib)
• The label expansion approval strengthens Roche's commitment to personalized healthcare by providing lung cancer patients with access to more treatment options
• The Ventana ALK (D5F3) CDx assay is now FDA approved as a CDx in four targeted treatments - Xalkori (crizotinib)- Zykadia (ceritinib)- Alecensa (alectinib) and Lorbrena (lorlatinib). The assay is the only IHC approved by the FDA as a CDx for Lorbrena

 ­ Ref: PRNewswire | Image: Roche